Homepage0853 • HKG
add
MicroPort Scientific Corp
Vorige slotkoers
$Â 12,46
Dag-range
$Â 12,73 - $Â 14,16
Jaar-range
$Â 5,53 - $Â 16,28
Beurswaarde
24,64Â mld. HKD
Gem. volume
16,96Â mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
HKG
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 273,77Â mln. | -2,00% |
Bedrijfskosten | 153,68Â mln. | -14,80% |
Netto inkomsten | -23,30Â mln. | 51,87% |
Netto winstmarge | -8,51 | 50,89% |
Winst per aandeel | — | — |
EBITDA | 26,04Â mln. | 99,76% |
Effectief belastingtarief | -86,95% | — |
Balans
Totale activa
Totale passiva
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 957,62Â mln. | -7,63% |
Totale activa | 3,77Â mld. | -0,59% |
Totale passiva | 2,59Â mld. | 3,36% |
Totaal aandelenvermogen | 1,18 mld. | — |
Uitstaande aandelen | 1,85 mld. | — |
Koers-boekwaardeverhouding | 36,65 | — |
Rendement op activa | 0,04% | — |
Rendement op kapitaal | 0,05% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | jun 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -23,30Â mln. | 51,87% |
Operationele kasstroom | -5,77Â mln. | 65,49% |
Kasstroom uit beleggingen | -3,17Â mln. | 96,31% |
Kasstroom uit financiering | 33,95Â mln. | 201,05% |
Nettomutatie in liquide middelen | 25,75Â mln. | 118,43% |
Vrije kasstroom | 12,88Â mln. | 421,18% |
Over
MicroPort is a multinational medical technology company with headquarters in Shanghai; Irvine, California; and Clamart, France. The company designs and produces medical devices across multiple therapeutic areas including interventional cardiology, orthopedics, cardiac rhythm management, electrophysiology, neurovascular intervention, structural heart disease, surgical robotics, and critical care.
MicroPort completed its initial public offering on the Hong Kong Stock Exchange in 2010 and has since established multiple specialized subsidiaries focused on distinct therapeutic areas, with several completing separate public listings. Recognized as one of the global Medtech Big 100 companies, MicroPort's coronary intervention products have been implanted in over 10 million patients globally since its founding, with devices distributed globally in over 90 countries across. Wikipedia
Opgericht
1998
Website
Werknemers
6.287